Company Profile
Madrigal Stock Price, News & Catalysts
- Ticker:
- MDGL
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
499.71 USD (-0.84%)
Close
Last updated: October 1, 2026
10.4B USD
Market cap
Why the stock is moving
As of Oct 1, 2026, MDGL closed down 0.84% at $499.71. No new same-company headline was identified in the current news window.
Company overview
MASH-Focused Biopharmaceutical Company
Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation. The company is building a specialized commercial and clinical-development organization around therapies that address both liver pathology and associated cardiometabolic risk.
Rezdiffra Commercial Franchise
Rezdiffra is an oral, liver-directed thyroid hormone receptor beta agonist approved for adults with noncirrhotic MASH and moderate-to-advanced fibrosis. It is the foundation of Madrigal's business and is supported by hepatology, gastroenterology, and endocrinology commercial coverage, disease education, and real-world evidence generation.
Lifecycle Expansion Into Cirrhosis
Madrigal is studying resmetirom in patients with well-compensated MASH cirrhosis, an adjacent population with substantial risk of liver-related events. The company has also expanded the product's intellectual-property estate with patents covering approved dosing and potential use in F4 compensated cirrhosis.
Combination-Therapy Strategy
MGL-2086 is an oral small-molecule GLP-1 receptor agonist being developed as a potential combination partner for Rezdiffra. Madrigal's strategy is to pair direct liver and antifibrotic activity with weight-loss and metabolic benefits in a once-daily oral regimen for MASH.
Future catalysts
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Madrigal (MDGL)?
Madrigal (MDGL) most recently closed at 499.71 USD, a -0.84% move versus the previous session.
What is the market cap of Madrigal (MDGL)?
Madrigal currently has a market capitalization of 10.4B USD on BioPharmSignal.
What does Madrigal do?
MASH-Focused Biopharmaceutical Company Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation. The company is building a specialized commercial and clinical-development organization around therapies that address both liver...
On which exchange is MDGL stock listed?
Madrigal (MDGL) is associated with NASDAQ, United States, Biopharma.
What is MGL-2086?
Combination-Therapy Strategy MGL-2086 is an oral small-molecule GLP-1 receptor agonist being developed as a potential combination partner for Rezdiffra.
Which conditions is Madrigal targeting with MGL-2086?
Madrigal is associated with cancer therapeutics, metabolic disease based on its company overview and current catalyst commentary.
What is GLP-1?
Combination-Therapy Strategy MGL-2086 is an oral small-molecule GLP-1 receptor agonist being developed as a potential combination partner for Rezdiffra.
What is MASH-Focused?
MASH-Focused Biopharmaceutical Company Madrigal Pharmaceuticals is focused on metabolic dysfunction-associated steatohepatitis, a progressive liver disease that can lead to cirrhosis, liver failure, cancer, and transplantation.